Anaemia is common in patients admitted to and discharged from intensive care (ICU) and is associated with poor quality of life in ICU survivors (Walsh et al, 2010; Lasocki et al, 2014) . The majority of ICU patients will have an anaemia of inflammation (AI) as a collective result of functional iron deficiency, leading to iron restricted erythropoiesis, increased cytokine production, suppressed bone marrow activity and reduced red blood cell life span (Lasocki et al, 2010) . Identifying iron deficiency in this context is challenging because commonly used tests, such as ferritin and transferrin saturation, are significantly confounded by inflammation.
Hepcidin is a circulating polypeptide, which, via its inhibitory action on the key iron exporter ferroportin, acts as a key regulator in iron homeostasis (Girelli et al, 2016) . Inhibition of ferroportin results in retention of iron within enterocytes, macrophages and hepatocytes with a consequent decrease in serum iron levels, thereby restricting its availability for erythropoiesis. Hepcidin expression is increased by inflammation and iron overload but reduced in iron deficiency, hypoxia and enhanced erythropoietic drive. Elevated hepcidin levels restricting the use of iron, along with suppressed bone marrow function, may partly explain why trials of iron supplementation in the acute phase of critical illness have not shown any benefit (Litton et al, 2016; Shah et al, 2016) . Hepcidin may be a better marker of iron deficiency (or requirement for iron) than the routine biochemical assays in current use, allowing more precise identification of anaemic patients likely to respond to iron therapy (Girelli et al, 2016) .
In order to identify a potential cohort of patients who would probably respond [i.e. increase haemoglobin (Hb) concentration] to iron supplementation, we investigated the utility of serum hepcidin concentrations of ICU survivors at hospital discharge. Patients recruited to the RECOVER (Evaluation of a Rehabilitation Complex Intervention for Patients Following Intensive Care Discharge) trial and who consented to a biomarker sub-study were eligible (Walsh et al, 2015) . RECOVER was a randomized controlled trial examining the effect of a complex rehabilitation package on physical outcome in ICU survivors.
Laboratory tests recorded included Hb concentration, serum creatinine, albumin and C-reactive protein (CRP). Serum hepcidin was measured by enzyme-linked immunosorbent assay (ELISA) (hepcidin-25 high sensitivity ELISA, DRG Instruments, Marburg, Germany). Other markers of iron status and erythropoiesis, such as ferritin, serum iron, transferrin saturation (Tsat), soluble transferrin receptor (sTfR), erythropoietin, vitamin B12 and folate, were also analysed.
Anaemia was defined according to World Health Organization (WHO) guidelines: males Hb <130 g/l and females Hb <120 g/l. A ferritin cut-off of <15 lg/l was used to diagnose iron deficiency anaemia (WHO, 2001) . In the presence of inflammation (defined as CRP >8 mg/l), a ferritin cut-off of 150 lg/l was used to differentiate between combined anaemia of iron deficiency and inflammation (IDI) (ferritin <150 lg/l) and AI (ferritin >150 lg/l) as previous reported (Lee et al, 2002) .
Baseline characteristics are shown in Table 1 . Median (interquartile range, IQR) CRP for the entire cohort was 36 (15-72) mg/l, reflecting ongoing inflammation even at hospital discharge. 110/117 (94%) patients were anaemic with a CRP of >8 mg/l prior to hospital discharge. Of these, 89/110 (81%) had AI and 11/110 (10%) had IDI (Table 2) . 10 patients developed anaemia that appeared unrelated to iron, B12, and/or folate deficiency or inflammation.
Laboratory results are shown in Table 2 . Median (IQR) serum hepcidin concentration was significantly lower in the IDI group and there was no statistical difference in CRP concentrations between both groups, indicating the difference in hepcidin values may not reflect a higher level of inflammation in the AI group. Levels of the sTfR-ferritin index, another potential marker of iron deficiency in inflammation, were higher in the IDI group and linear regression of (log) sTfR-ferritin index with (log) hepcidin showed a strong association (co-efficient À0Á8, P < 0Á001). There were no significant differences in age, illness severity, Hb and renal function between both groups. The maximal Youden index was achieved at a hepcidin cut-off of <19 ng/ml, with a sensitivity of 73% and specificity of 74%. Using current definitions of iron deficiency, 11/110 patients would be considered eligible for oral iron replacement. Applying a hepcidin cut-off <19 ng/ml, a further 24 patients would be included, raising this to 32% of the anaemic cohort.
This study has confirmed a high prevalence of anaemia at time of hospital discharge in ICU survivors (Walsh et al, 2010) . While inflammatory processes are still active in this patient group, as evidenced by the raised median CRP in the entire cohort, up to one-third of inflamed and anaemic patients had a hepcidin level <19 ng/ml, a cut-off with maximal sensitivity and specificity for identifying iron deficiency.
To our knowledge, only one other study has assessed the diagnostic accuracy of hepcidin in ICU patients [Lasocki et al, 2010; ] . The authors proposed a threshold value of hepcidin <129Á5 ng/ml to identify iron deficiency in critically ill patients. We propose prospectively investigating a cut-off of 19 ng/ml to guide treatment with oral iron in patients recovering from critical illness as this achieved the highest combined sensitivity and specificity. However, this cut-off is only applicable with the specific assay we used. The differences in threshold levels between our study and the one reported by Lasocki et al (2010) can therefore partly be explained by differences in assays used, as the absolute numbers reported for the same concentrations will be different.
Hepcidin levels may have a potential role in guiding iron therapy as demonstrated in other non-critically ill populations where low hepcidin levels can facilitate oral iron absorption (Pasricha et al, 2014; Girelli et al, 2016) . Within this categorisation will be patients with low hepcidin concentrations and no evidence of iron deficiency by current parameters, but who could still have iron-responsive anaemia due to their low hepcidin levels and ability to absorb iron. Although patients with high hepcidin concentrations are unlikely to absorb oral iron, they may still benefit from intravenous iron, which can bypass the 'hepcidin-block'. Prospective studies are justified to determine whether targeted iron therapy can improve recovery from ICU-related anaemia with subsequent improvements in quality of life.
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